Purpose: The blinq (Rebion Inc) is a new screening device designed to directly detect amblyopia and strabismus rather than amblyopia risk factors. We performed an independent assessment of the effectiveness of the blinq in detecting amblyopia and strabismus.
Design: Prospective clinical validity analysis of a screening device based on sensitivity and specificity.